Literature DB >> 17131194

Pair-wise interactions of polymerization inhibitory contact site mutations of hemoglobin-S.

Sonati Srinivasulu1, Krishnaveni Perumalsamy, Rajendra Upadhya, Belur N Manjula, Steven Feiring, Raouf Alami, Eric Bouhassira, Mary E Fabry, Ronald L Nagel, A Seetharama Acharya.   

Abstract

The linkage of pair-wise interactions of contact site mutations of HbS has been studied using Le Lamentin [His-20 (alpha)-->Gln], Hoshida [Glu-43 (beta)-->Gln] and alpha(2)beta (2) (T87Q) mutations as the prototype of three distinct classes of contact sites of deoxy HbS fiber. Binary mixture experiments established that beta(A)-chain with the Thr-87 (beta)-->Gln mutation is as potent as the gamma-chain of HbF (alpha(2)gamma(2)) in inhibiting polymerization. On combining the influence of Le Lamentin mutation with that of beta (2) (T87Q) mutations; the net influence is only partial additivity. On the other hand, in binary mixture studies, combined influence of Hoshida mutation with that of beta (2) (T87Q) mutations is synergistic. Besides, a significant level of synergistic complementation is also seen when the Le Lamentin and Hoshida mutations are combined in HbS (symmetrical tetramers). Le Lamentin and Hoshida mutation introduced into the cis-dimer of the asymmetric hybrid tetramer completely neutralizes the Val-6 (beta) dependent polymerization. Accordingly, we propose that combining the perturbation of intra-double strand contact site with that of an inter-double strand contact site exhibit synergy when they are present in two different chains of the alphabeta dimer. A comparison of the present results with that of the earlier studies suggest that when the two contact site perturbations are from the same sub-unit of the alphabeta dimer only partial additivity is observed. The map of interaction linkage of the contact site mutations exposes new strategies in the design of novel anti-sickling Hbs for the gene therapy of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131194     DOI: 10.1007/s10930-006-9034-3

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  34 in total

1.  Sickle cell disease in a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori.

Authors:  H E Witkowska; B H Lubin; Y Beuzard; S Baruchel; D W Esseltine; E P Vichinsky; K M Kleman; J Bardakdjian-Michau; L Pinkoski; S Cahn
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

2.  A recombinant sickle hemoglobin triple mutant with independent inhibitory effects on polymerization.

Authors:  J P Himanen; U A Mirza; B T Chait; R M Bookchin; J M Manning
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

3.  Molecular analysis of the human beta-globin locus activation region.

Authors:  W C Forrester; U Novak; R Gelinas; M Groudine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Nucleation-controlled aggregation of deoxyhemoglobin S. Possible difference in the size of nuclei in different phosphate concentrations.

Authors:  K Adachi; T Asakura
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

5.  Some functional properties of hemoglobin Leiden.

Authors:  R L Nagel; R F Rieder; R M Bookchin; G W James
Journal:  Biochem Biophys Res Commun       Date:  1973-08-21       Impact factor: 3.575

6.  Interspecies hybrid HbS: complete neutralization of Val6(beta)-dependent polymerization of human beta-chain by pig alpha-chains.

Authors:  M J Rao; A Malavalli; B N Manjula; R Kumar; M Prabhakaran; D P Sun; N T Ho; C Ho; R L Nagel; A S Acharya
Journal:  J Mol Biol       Date:  2000-07-28       Impact factor: 5.469

7.  A protein sequenator.

Authors:  P Edman; G Begg
Journal:  Eur J Biochem       Date:  1967-03

8.  A mouse model for beta 0-thalassemia.

Authors:  B Yang; S Kirby; J Lewis; P J Detloff; N Maeda; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

9.  Recombinant human hemoglobins designed for gene therapy of sickle cell disease.

Authors:  S L McCune; M P Reilly; M J Chomo; T Asakura; T M Townes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

10.  Hemoglobin Einstein: semisynthetic deletion in the B-helix of the alpha-chain.

Authors:  Sonati Srinivasulu; Belur N Manjula; Ronald L Nagel; Ching-Hsuan Tsai; Chien Ho; Muthuchidambaran Prabhakaran; Seetharama A Acharya
Journal:  Protein Sci       Date:  2004-05       Impact factor: 6.725

View more
  4 in total

1.  Sickle Cell Hemoglobin with Mutation at αHis-50 Has Improved Solubility.

Authors:  Ming F Tam; Tsuey Chyi S Tam; Virgil Simplaceanu; Nancy T Ho; Ming Zou; Chien Ho
Journal:  J Biol Chem       Date:  2015-07-16       Impact factor: 5.157

2.  Structural basis for the antipolymer activity of Hb ζ2βs2 trapped in a tense conformation.

Authors:  Martin K Safo; Tzu-Ping Ko; Eric R Schreiter; J Eric Russell
Journal:  J Mol Struct       Date:  2015-11-05       Impact factor: 3.196

3.  Modification of axial fiber contact residues impact sickle hemoglobin polymerization by perturbing a network of coupled interactions.

Authors:  Srijita Banerjee; Neda Mirsamadi; Lavanya Anantharaman; Mylavarapu V S Sivaram; Rasik B Gupta; Devapriya Choudhury; Rajendra P Roy
Journal:  Protein J       Date:  2007-10       Impact factor: 2.371

4.  βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells.

Authors:  Selami Demirci; Bjorg Gudmundsdottir; Quan Li; Juan J Haro-Mora; Tina Nassehi; Claire Drysdale; Morgan Yapundich; Jackson Gamer; Fayaz Seifuddin; John F Tisdale; Naoya Uchida
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.